Pfizer and BioNTech have signed a letter of intent with Biovac, a Cape City-based biopharmaceutical firm, to manufacture the Pfizer-BioNTech Covid-19 vaccine for distribution inside the African Union.
To facilitate Biovac’s involvement in the method, technical switch, on-site improvement and gear set up actions will start instantly, Pfizer stated in a press assertion on Wednesday (21 July).
Pfizer and BioNTech stated they count on that Biovac’s Cape City facility will be included into the vaccine provide chain by the tip of 2021.
Biovac will get hold of drug substances from amenities in Europe, and manufacturing of completed doses will start in 2022.
At full operational capability, the annual manufacturing will exceed 100 million completed doses yearly and all doses will solely be distributed inside the 55 member states that make up the African Union.
“From day one, our goal has been to provide fair and equitable access of the Pfizer-BioNTech Covid-19 Vaccine to everyone, everywhere,” stated Albert Bourla, chief govt of Pfizer.
“Our newest collaboration with Biovac is a shining instance of the tireless work being executed, in this occasion to profit Africa.
“We will continue to explore and pursue opportunities to bring new partners into our supply chain network, including in Latin America, to further accelerate access of Covid-19 vaccines.”
Biovac is aiming to begin manufacturing of the mRNA Covid-19 vaccine in the second half of subsequent yr, its chief govt officer Morena Makhoana instructed Reuters.
Makhoana stated that the agency would ramp up manufacturing of the Covid-19 vaccine earlier than reaching output of 100 million doses a yr round early 2023.